Abstract PS5-08-25: ReDiscover-2, a phase 3 study of RLY-2608 + fulvestrant versus capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor (trial in progress)
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: City Of Hope National Medical Center, City of Hope, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Memorial Sloan Kettering Cancer Center, Hospital São Lucas da PUCRS, Pontifícia Universidade Católica do Rio Grande do Sul, Peter MacCallum Cancer Centre, University Medical Centre Mannheim, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Institut Curie, Samsung Medical Center, Barts Cancer Institute, Dana-Farber Cancer Institute, University of Milan, European Institute of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129468486
Cites:
Cited by:
Related to: